UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
April 25, 2018
(Date of earliest event reported)
LABORATORY CORPORATION OF
AMERICA HOLDINGS
(Exact Name of Registrant as Specified in its Charter)
Delaware | 1-11353 | 13-3757370 | ||
(State or other jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||
358 South Main Street, | ||||
Burlington, North Carolina | 27215 | 336-229-1127 | ||
(Address of principal executive offices) | (Zip Code) | (Registrant’s telephone number including area code) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |
Item 9.01 | Financial Statements and Exhibits | |
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant
By: | /s/ F. SAMUEL EBERTS III | |
F. Samuel Eberts III | ||
Chief Legal Officer and Secretary | ||
April 25, 2018
8-K FURNISHED APRIL 25, 2018
FIRST QUARTER 2018
SUPPLEMENTAL FINANCIAL INFORMATION
1
FORWARD LOOKING STATEMENT
This presentation contains forward-looking statements including but not limited to statements with
respect to estimated 2018 guidance and the related assumptions, the impact of various factors on
operating and financial results, expected savings and synergies (including from the LaunchPad
initiative and as a result of acquisitions), and the opportunities for future growth.
This presentation contains forward-looking statements which are subject to change based on various
important factors, including without limitation, competitive actions and other unforeseen changes and
general uncertainties in the marketplace, changes in government regulations, including health care
reform, customer purchasing decisions, including changes in payer regulations or policies, other
adverse actions of governmental and third-party payers, changes in testing guidelines or
recommendations, adverse results in material litigation matters, the impact of changes in tax laws and
regulations, failure to maintain or develop customer relationships, our ability to develop or acquire
new products and adapt to technological changes, failures in information technology systems or data
security, challenges in implementing business process changes, employee relations, and the effect of
exchange rate fluctuations on international operations.
Actual results could differ materially from those suggested by these forward-looking statements. The
Company has no obligation to provide any updates to these forward-looking statements even if its
expectations change. Further information on potential factors, risks and uncertainties that could affect
the operating and financial results of Laboratory Corporation of America Holdings (the “Company”) is
included in the Company’s Form 10-K for the year ended December 31, 2017, and subsequent Forms
10-Q, including in each case under the heading risk factors, and in the Company’s other filings with
the SEC. The information in this presentation should be read in conjunction with a review of the
Company’s filings with the SEC including information in the Company’s Form 10-K for the year ended
December 31, 2017, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS.
2
USE OF ADJUSTED MEASURES AND ADOPTION OF ASC 606
The Company has provided in this presentation “adjusted” financial information that has
not been prepared in accordance with GAAP, including Adjusted EPS, Adjusted Operating
Income, Adjusted EBITDA, Free Cash Flow, and certain segment information. The
Company believes these adjusted measures are useful to investors as a supplement to,
but not as a substitute for, GAAP measures, in evaluating the Company’s operational
performance. The Company further believes that the use of these non-GAAP financial
measures provides an additional tool for investors in evaluating operating results and
trends, and growth and shareholder returns, as well as in comparing the Company’s
financial results with the financial results of other companies. However, the Company
notes that these adjusted measures may be different from and not directly comparable to
the measures presented by other companies. Reconciliations of these non-GAAP
measures to the most comparable GAAP measures are included in the tables
accompanying this presentation.
Effective January 1, 2018, the Company adopted the FASB-issued converged standard on
revenue recognition (ASC 606), using the full retrospective method. Unless otherwise
indicated, all financial results in 2016 and 2017 and comparisons to financial results in
2016 and 2017 have been restated in this presentation as if the Company had adopted
ASC 606 on January 1 of the relevant year. This accounting change affects the
Company’s Diagnostics and Drug Development businesses differently, as explained in
this presentation; for the enterprise, the accounting change increases revenue, lowers
earnings, and has no impact on cash flow.
3
FIRST QUARTER CONSOLIDATED RESULTS(1)
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
(1) The table presented above reflects the application of ASU 2017-17 for all periods presented. This application increased LabCorp Diagnostics adjusted
operating income in the first quarter of 2017 by $0.8 million and reduced Covance Drug Development adjusted operating income by $1.1 million.
These reclassifications have no impact on the Company's net earnings or its EPS.
(2) Adjusted operating income and adjusted EPS exclude amortization, restructuring charges and special items.
(3) See Reconciliation of non-GAAP Financial Measures on slides 17 – 20.
(4) Operating cash flow in 2017 has been reduced by $7.9 million as the result of implementation of ASU 2016-18. This amount represents the amount of
historical payments made on the Company’s zero-coupon subordinated notes deemed to be accreted interest.
(5) The increase in revenue was due to growth from acquisitions of 13.4%, organic growth (total revenue less revenue from acquisitions for the first twelve
months after the close of each acquisition) of 3.2%, and the benefit from foreign currency translation of approximately 150 basis points.
Restated for ASC 606
and ASU 2017-17
1Q18 1Q17 % Change
Revenue $2,848.3 $2,413.7 18.0%
Adjusted Operating Income(2) (3) $435.7 $376.7 15.7%
Adjusted Operating Margin 15.3% 15.6% (30 bps)
Adjusted EPS(2) (3) $2.78 $2.13 30.5%
Operating Cash Flow(4) $154.7 $225.9 (31.5%)
Less: Capital Expenditures ($72.5) ($72.2) (0.4%)
Free Cash Flow $82.2 $153.7 (46.5%)
(5)
4
FIRST QUARTER PRO FORMA SEGMENT RESULTS(1)
(DOLLARS IN MILLIONS, EXCEPT PER SHARE DATA)
LABORATORY CORPORATION OF AMERICA HOLDINGS
Condensed Combined Non-GAAP Pro Forma Segment Information
Current Revenue Recognition Prior Revenue Recognition
Accounting Standard (ASC 606) Accounting Standard (ASC 605) ASC 606 vs ASC 605
Three Months Ended
March 31, 2018(3)
2018 2017(2) Change 2018(3) 2017(2) Change Change
LabCorp Diagnostics
Revenues 1,770.2$ 1,639.7$ 8.0% 1,855.5$ 1,717.9$ 8.0% ($85.3)
Adjusted Operating Income (4) (5) 364.0$ 341.8$ 6.5% 364.0$ 341.8$ 6.5% $0.0
Adjusted Operating Margin 20.6% 20.8% (30 bps) 19.6% 19.9% (30 bps) 90 bps
Covance Drug Development
Revenues 1,078.5$ 774.2$ 39.3% 882.8$ 690.3$ 27.9% $195.7
Adjusted Operating Income (4) (5) 108.0$ 68.1$ 58.6% 114.7$ 82.4$ 39.2% ($6.7)
Adjusted Operating Margin 10.0% 8.8% 120 bps 13.0% 11.9% 110 bps (300 bps)
Consolidated
Revenues 2,848.3$ 2,413.7$ 18.0% 2,738.0$ 2,408.1$ 13.7% $110.3
Adjusted Segment Operating Income (4) (5) 472.0$ 409.9$ 15.2% 478.7$ 424.2$ 12.8% ($6.7)
Unallocated corporate expense (36.3)$ (33.2)$ -9.3% (36.3)$ (33.2)$ -9.3% $0.0
Consolidated Adjusted Operating Income (4) (5) 435.7$ 376.7$ 15.7% 442.4$ 391.0$ 13.1% ($6.7)
Adjusted Operating Margin 15.3% 15.6% (30 bps) 16.2% 16.2% (10 bps) (90 bps)
Adjusted EPS (4) (5) 2.78$ 2.13$ 30.5% 2.83$ 2.22$ 27.5% ($0.05)
(3) For comparative purposes, the Company estimated its results under the prior accounting standard (ASC 605).
(4) Adjusted operating income and adjusted EPS exclude amortization, restructuring charges and special items.
(5) See Reconciliation of non-GAAP Financial Measures on slides 17 – 20.
Three Months Ended
March 31,
Three Months Ended
March 31,
(1) The consolidated revenue and adjusted operating income are presented net of inter-segment transaction eliminations. In addition, the tables presented above
reflect the application of ASU 2017-17 for all periods presented. This application increased LabCorp Diagnostics adjusted operating income in the first quarter of 2017
by $0.8 million and reduced Covance Drug Development adjusted operating income by $1.1 million. These reclassifications have no impact on the Company's net
earnings or its EPS.
(2) Covance Drug Development’s results exclude the impact from the wind-down of operations relating to a committed minimum volume contract that expired on
October 31, 2015.
5
SELECT FINANCIAL METRICS
(DOLLARS IN MILLIONS)
Restated for ASC 606 and ASU 2017-17
1Q17 2Q17 3Q17 4Q17 1Q18
Total Depreciation $78.4 $73.5 $76.4 $78.5 $78.3
Total Amortization(1) $47.6 $51.4 $54.6 $62.9 $62.3
Total Adjusted EBITDA(2) $457.5 $509.6 $511.8 $512.7 $517.2
Total Debt to Last Twelve Months Adjusted EBITDA(2)(3) 3.2x 3.2x 3.6x 3.3x 3.3x
Total Net Debt to Last Twelve Months Adjusted EBITDA(2)(3)(4) 3.0x 3.1x 3.4x 3.2x 3.1x
(1) Excludes amortization of deferred financing fees.
(2) Adjusted EBITDA excludes restructuring charges and special items. See reconciliation on slide 16.
(3) Leverage ratios beginning with the third quarter of 2017 include Chiltern Adjusted EBITDA from the twelve months prior to the relevant period on a pro forma basis.
(4) Net debt equals total debt less cash and cash equivalents.
6
COVANCE DRUG DEVELOPMENT: SELECT FINANCIAL METRICS UNDER ASC 606(1)
Trailing Twelve Month (TTM) Results
Net Orders Net Book-to-Bill
TTM Ending March 31, 2018(2) $4.8 billion 1.29x
TTM Ending December 31, 2017(2) $4.6 billion 1.34x
Backlog
Estimated revenue expected to convert
from backlog in the next twelve months
As of March 31, 2018(3) $9.2 billion $3.7 billion
As of December 31, 2017 $8.7 billion
(1) Results shown include the impact from cancellations and foreign currency translation.
(2) Includes results from Chiltern following the closing of the acquisition on September 1, 2017.
(3) Included backlog from the acquisition of Global Specimen Solutions of approximately $65 million.
7
COVANCE DRUG DEVELOPMENT: SELECT FINANCIAL METRICS UNDER ASC 605(1)
Trailing Twelve Month (TTM) Results
Net Orders Net Book-to-Bill
TTM Ending March 31, 2018(2) $4.3 billion 1.34x
TTM Ending December 31, 2017(2) $4.1 billion 1.36x
TTM Ending September 30, 2017(2) $3.8 billion 1.33x
TTM Ending June 30, 2017 $3.4 billion 1.23x
TTM Ending March 31, 2017 $3.2 billion 1.15x
Backlog
Estimated revenue expected to convert
from backlog in the next twelve months
As of March 31, 2018(3) $7.6 billion $3.1 billion
As of December 31, 2017 $7.1 billion $2.8 billion
As of September 30, 2017(4) $6.8 billion $2.7 billion
As of June 30, 2017 $5.5 billion $2.1 billion
As of March 31, 2017 $5.2 billion $2.1 billion
(1) Results shown include the impact from cancellations and foreign currency translation.
(2) Includes results from Chiltern following the closing of the acquisition on September 1, 2017.
(3) Included backlog from the acquisition of Global Specimen Solutions of approximately $65 million.
(4) Included backlog from the acquisition of Chiltern of approximately $1.0 billion.
8
(1) Revenues recognized in over 30 currencies; the largest foreign currency accounts for less than 10% of total revenue.
Segment Distribution
LabCorp
Diagnostics
62.1%
Covance
Drug Development
37.9%
USA
78.0%
Geographic Distribution
Rest of
World(1)
22.0%
FIRST QUARTER 2018 REVENUE DISTRIBUTION
9
FIRST QUARTER 2018 FOREIGN EXCHANGE IMPACT TO REVENUE(1)
(DOLLARS IN MILLIONS)
Year over Year
Dollars % Growth
Consolidated
Revenue, as Reported $2,848 18.0%
Foreign Exchange Impact ($35) (1.5%)
Revenue, Constant Currency $2,813 16.5%
LabCorp Diagnostics
Revenue, as Reported $1,770 8.0%
Foreign Exchange Impact ($5) (0.3%)
Revenue, Constant Currency $1,765 7.7%
Covance Drug Development
Revenue, as Reported $1,078 39.3%
Foreign Exchange Impact ($30) (3.9%)
Revenue, Constant Currency $1,048 35.4%
(1) Does not tie due to rounding.
10
2017 FINANCIAL RESULTS RESTATED FOR ASC 606(1)
Effective January 1, 2018, the Company adopted the FASB-issued converged standard on revenue recognition (ASC 606), using the full
retrospective method. The table below presents the Company’s restated financial results in 2017, and is being provided as a reference for the
Company’s financial performance and guidance in 2018. The adoption of ASC 606 had no impact on cash flow; however, it resulted in higher
revenue, as well as lower adjusted operating income, adjusted operating margin and adjusted EPS in 2017.
(1) The Company will apply the provisions of ASU 2017-17 (Improving the Presentation of Net Periodic Pension Cost and Net Periodic Post-Retirement
Benefit Cost) to all 2017 periods presented. For the year ended December 31, 2017, the application of this accounting standard will decrease operating
income and decrease other operating expenses by a net $2.5 million, with no impact on net income or EPS. For full-year 2017, this reclassification will
increase LabCorp Diagnostics’ adjusted operating income by $2.3 million and decrease Covance Drug Development’s adjusted operating income by
$4.8 million. To highlight the change resulting from ASC 606, the reclassification related to ASU 2017-17 has not been reflected in the table above.
(2) In LabCorp Diagnostics, the impact of the accounting change reduced revenue and increased margins, as bad debt is treated as a reduction in revenue
rather than selling, general and administrative expense. The accounting change had no impact on adjusted operating income or cash flow.
(3) In Covance Drug Development, the impact of the accounting change increased backlog, revenue and cost of revenue due to the inclusion of investigator
fees and other pass-through expenses in all categories. In addition, the inclusion of investigator fees and other pass-through expenses changes the
underlying percentage of completion calculation used to recognize revenue. As a result, the restated financials for 2017 reflect lower operating margins
and a deferral of previously recognized earnings. The accounting change had no impact on cash flow.
(Dollars in millions, except per share data) Dollar Percent
Restatement As Reported Change Change
LabCorp Diagnostics (2)
Revenues 6,858.0$ 7,170.5$ (312.5)$ -4.4%
Adjusted Operating Income 1,446.3$ 1,446.3$ -$ 0.0%
Adjusted Operating Margin 21.1% 20.2% 90 bps
Covance Drug Development (3)
Revenues 3,451.5$ 3,037.2$ 414.3$ 13.6%
Adjusted Operating Income 366.0$ 422.4$ (56.4)$ -13.4%
Adjusted Operating Margin 10.6% 13.9% (330 bps)
Consolidated (2) (3)
R venues 10,307.7$ 10,205.9$ 101.8$ 1.0%
Adjusted Segment Operating Income 1,812.3$ 1,868.7$ (56.4)$ -3.0%
Unallocated corporate expense (137.4)$ (137.4)$ -$ 0.0%
Consolidated Adjusted Operating Income 1,674.9$ 1,731.3$ (56.4)$ -3.3%
Adjusted Operating Margin 16.2% 17.0% (70 bps)
Adjusted EPS $9.25 $9.60 ($0.35) -3.6%
Twelve Months Ended
December 31, 2017
Twelve Months Ended
December 31, 2017
11
2017 QUARTERLY SEGMENT FINANCIAL RESULTS
RESTATED FOR ASC 606 AND ASU 2017-17(1)
(1) The table presented above reflects the application of ASU 2017-17 for all periods presented.
(2) In LabCorp Diagnostics, the impact of the accounting change reduced revenue and increased margins, as bad debt is treated as a reduction in revenue rather than selling,
general and administrative expense. The accounting change had no impact on adjusted operating income or cash flow.
(3) In Covance Drug Development, the impact of the accounting change increased backlog, revenue and cost of revenue due to the inclusion of investigator fees and other pass-
through expenses in all categories. In addition, the inclusion of investigator fees and other pass-through expenses changes the underlying percentage of completion
calculation used to recognize revenue. As a result, the restated financials for 2017 reflect lower operating margins and a deferral of previously recognized earnings. The
accounting change had no impact on cash flow.
(Dollars in millions, except per share data)
Three Months Ended
March 31, 2017
Three Months Ended
June 30, 2017
Three Months Ended
September 30, 2017
Three Months Ended
December 31, 2017
Twelve Months Ended
December 31, 2017
LabCorp Diagnostics (2)
Revenues 1,639.7$ 1,721.1$ 1,754.7$ 1,742.7$ 6,858.0$
Adjusted Operating Income 341.8$ 375.5$ 374.3$ 357.0$ 1,448.6$
Adjusted Operating Margin 20.8% 21.8% 21.3% 20.5% 21.1%
Covance Drug Development (3)
Revenues 774.2$ 807.5$ 867.1$ 1,002.8$ 3,451.5$
Adjusted Operating Income 68.1$ 88.5$ 93.8$ 110.9$ 361.2$
Adjusted Operating Margin 8.8% 11.0% 10.8% 11.1% 10.5%
Consolidated (2) (3)
Revenues 2,413.7$ 2,528.1$ 2,621.4$ 2,744.7$ 10,307.7$
Adjusted Segment Operating Income 409.9$ 464.0$ 468.1$ 467.9$ 1,809.7$
Unallocated corporate expense (33.2)$ (33.2)$ (36.2)$ (35.2)$ (137.4)$
Consolidated Adjusted Operating Income 376.7$ 430.8$ 431.9$ 432.7$ 1,672.3$
Adjusted Operating Margin 15.6% 17.0% 16.5% 15.8% 16.2%
Adjusted EPS 2.13$ 2.43$ 2.37$ 2.31$ 9.25$
12
2017 QUARTERLY FINANCIAL RESULTS – GAAP BASIS
RESTATED FOR ASC 606 AND ASU 2017-17
The table presented
includes
approximately $79.7
million of special
items in selling,
general and
administrative
expenses in full-year
2017.
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS - RESTATED FOR ASC 606 AND ASU 2017-17
(Dollars in Millions, except per share data)
Quarter Ended Quarter Ended Quarter Ended Quarter Ended Year Ended
March 31, 2017 June 30, 2017 September 30, 2017 December 31, 2017 December 31, 2017
Total revenues 2,413.7 2,528.2 2,621.4$ 2,744.4$ 10,307.7$
Total cost of revenues 1,702.6 1,750.0 1,835.2 1,925.5 7,213.3
Gross profit 711.1 778.2 786.2 818.9 3,094.4
Selling, general and administrative expenses 341.5 357.8 383.3 419.2 1,501.8
Amortization of intangibles and other assets 47.6 51.4 54.6 62.9 216.5
Restructuring and other special charges 3.9 39.1 21.6 6.3 70.9
Operating income 318.1 329.9 326.7 330.5 1,305.2
Other income (expense):
Interest expense (52.4) (55.0) (59.9) (67.8) (235.1)
Equity method income, net 2.3 4.5 3.2 1.3 11.3
Investment income 0.3 0.4 0.7 0.7 2.1
Other, net (3.0) (0.5) (3.9) 1.4 (6.0)
Earnings before income taxes 265.3 279.3 266.8 266.1 1,077.5
Provision (benefit) for income taxes 82.0 94.1 92.5 (424.0) (155.4)
Net earnings 183.3 185.2 174.3 690.1 1,232.9
Less: Net earnings attributable to the noncontrolling
interest (0.3) (0.3) (2.8) (2.4) (5.8)
Net earnings attributable to Laboratory Corporation
of America Holdings 183.0$ 184.9$ 171.5$ 687.7$ 1,227.1$
Basic earnings per common share 1.79$ 1.80$ 1.68$ 6.73$ 11.99$
Diluted earnings per common share 1.75$ 1.78$ 1.65$ 6.63$ 11.81$
Weighted average basic shares outstanding 102.5 102.4 102.3 102.2 102.4
Weighted average diluted shares outstanding 104.3 103.7 103.7 103.7 103.9
13
2017 QUARTERLY SEGMENT FINANCIAL RESULTS
REPORTED UNDER ASC 605 AND RESTATED FOR ASU 2017-17(1)
(1) The table presented above reflects the application of ASU 2017-17 for all periods presented.
(Figures in millions, except per share data)
Three Months Ended
March 31, 2017
Three Months Ended
June 30, 2017
Three Months Ended
September 30, 2017
Three Months Ended
December 31, 2017
Twelve Months Ended
December 31, 2017
LabCorp Diagnostics
Revenues 1,717.9$ 1,799.1$ 1,837.2$ 1,816.3$ 7,170.5$
Adjusted Operating Income 341.8$ 375.5$ 374.3$ 357.0$ 1,448.6$
Adjusted Operating Margin 19.9% 20.9% 20.4% 19.7% 20.2%
Covance Drug Development
Revenues 690.3$ 699.7$ 761.1$ 886.1$ 3,037.2$
Adjusted Operating Income 82.4$ 93.9$ 107.7$ 133.6$ 417.6$
Adjusted Operating Margin 11.9% 13.4% 14.2% 15.1% 13.7%
Consolidated
Revenues 2,408.1$ 2,498.4$ 2,597.9$ 2,701.6$ 10,205.9$
Adjusted Segment Operating Income 424.2$ 469.4$ 482.0$ 490.6$ 1,866.2$
Unallocated corporate expense (33.2)$ (33.2)$ (36.2)$ (35.2)$ (137.4)$
Consolidated Adjusted Operating Income 391.0$ 436.2$ 445.8$ 455.4$ 1,728.8$
Adjusted Operating Margin 16.2% 17.5% 17.2% 16.9% 16.9%
Adjusted EPS 2.22$ 2.47$ 2.46$ 2.45$ 9.60$
14
Effective January 1, 2018, the Company adopted the FASB-issued converged standard on revenue recognition (ASC 606), using the full retrospective
method. The table below presents the Company’s restated financial results in 2016. The adoption of ASC 606 had no impact on cash flow; however,
it resulted in higher revenue, as well as lower adjusted operating income, adjusted operating margin and adjusted EPS in 2016.
2016 FINANCIAL RESULTS RESTATED FOR ASC 606(1)
(1) The Company will apply the provisions of ASU 2017-17 (Improving the Presentation of Net Periodic Pension Cost and Net Periodic Post-Retirement
Benefit Cost) to all 2016 periods presented. To highlight the change resulting from ASC 606, the reclassification related to ASU 2017-17 has not been
reflected in the table above.
(2) In LabCorp Diagnostics, the impact of the accounting change reduced revenue and increased margins, as bad debt is treated as a reduction in revenue
rather than selling, general and administrative expense. The accounting change had no impact on adjusted operating income or cash flow.
(3) In Covance Drug Development, the impact of the accounting change increased backlog, revenue and cost of revenue due to the inclusion of investigator
fees and other pass-through expenses in all categories. In addition, the inclusion of investigator fees and other pass-through expenses changes the
underlying percentage of completion calculation used to recognize revenue. As a result, the restated financials for 2016 reflect lower operating margins
and a deferral of previously recognized earnings. The accounting change had no impact on cash flow.
(Dollars in millions, except per share data) Dollar Percent
Restatement As Reported Change Change
LabCorp Diagnostics (2)
Revenues 6,307.6$ 6,593.9$ (286.3)$ -4.3%
Adjusted Operating Income 1,322.9$ 1,322.9$ -$ 0.0%
Adjusted Operating Margin 21.0% 20.1% 90 bps
Covance Drug Development (3)
Revenues 3,245.8$ 2,842.2$ 403.6$ 14.2%
Adjusted Operating Income 380.5$ 412.7$ (32.2)$ -7.8%
Adjusted Operating Margin 11.7% 14.5% (280 bps)
Consolidated (2) (3)
Revenues 9,552.9$ 9,435.6$ 117.3$ 1.2%
Adjusted Segment Operating Income 1,703.4$ 1,735.6$ (32.2)$ -1.9%
Unallocated corporate expense (145.4)$ (145.4)$ -$ 0.0%
Consolidated Adjusted Operating Income 1,558.0$ 1,590.2$ (32.2)$ -2.0%
Adjusted Operating Margin 16.3% 16.9% (60 bps)
Adjusted EPS $8.63 $8.83 ($0.20) -2.3%
Twelve Months Ended
December 31, 2016
Twelve Months Ended
December 31, 2016
15
2018 FINANCIAL GUIDANCE
Prior Guidance
(assumes foreign exchange
rates effective as of
December 31, 2017)
Current Guidance
(assumes foreign exchange
rates effective as of
March 31, 2018)
Total revenue growth(1): 9.5% – 11.5%(3) 10.0% – 12.0%(4)
LabCorp Diagnostics revenue growth(1): 3.0% – 5.0%(5) 3.5% – 5.5%(6)
Covance Drug Development revenue growth(1): 20.0% – 24.0%(7) 21.0% – 25.0%(8)
Adjusted EPS(2): $11.30 – $11.70 $11.30 – $11.70
Free cash flow: $1.1 billion – $1.2 billion $1.1 billion – $1.2 billion
(1) Calculated based on the restatement of revenue in 2017 related to the Company’s adoption of ASC 606 effective January 1, 2018 shown on slide 10.
(2) Excludes the impact from amortization, restructuring charges and special items.
(3) Included the benefit of approximately 60 basis points of foreign currency translation.
(4) Includes the benefit of approximately 90 basis points of foreign currency translation.
(5) Included the benefit of approximately 20 basis points of foreign currency translation.
(6) Includes the benefit of approximately 20 basis points of foreign currency translation.
(7) Included the benefit of approximately 140 basis points of foreign currency translation.
(8) Includes the benefit of approximately 230 basis points of foreign currency translation.
16
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES – ADJUSTED EBITDA
(DOLLARS IN MILLIONS)
Restated for ASC 606 and ASU 2017-17
1Q17 2Q17 3Q17 4Q17 1Q18
LabCorp Operating Income $318.1 $329.9 $326.7 $330.5 $305.4
Add:
Restructuring and other special charges $3.9 $39.1 $21.6 $6.3 $14.3
Other special charges(1) $7.0 $10.8 $29.0 $32.8 $53.7
Depreciation $78.4 $73.5 $76.4 $78.5 $78.3
Amortization $47.6 $51.4 $54.6 $62.9 $62.3
Equity method income, net $2.3 $4.5 $3.2 $1.3 $2.5
Depreciation and amortization of equity method investments $0.2 $0.4 $0.3 $0.4 $0.7
Adjusted EBITDA $457.5 $509.6 $511.8 $512.7 $517.2
(1) Other special charges as disclosed by the Company in its quarterly earnings releases.
17
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
Adjusted Operating Income 2018 2017
Operating income 305.4$ 318.1$
Acquisition-related costs 17.9 4.4
Restructuring and other special charges 14.3 3.9
Consulting fees and executive transition expenses 3.1 -
Special tax reform bonus for employees 31.0 -
LaunchPad system implementation costs 1.7 2.7
Amortization of intangibles and other assets 62.3 47.6
Adjusted operating income 435.7$ 376.7$
Adjusted EPS
Diluted earnings per common share 1.67$ 1.75$
Restructuring and special items 0.50 0.07
Tax reform act adjustments 0.15 -
Amortization expense 0.46 0.31
Adjusted EPS 2.78$ 2.13$
LABORATORY CORPORATION OF AMERICA HOLDINGS
Reconciliation of Non-GAAP Financial Measures
(Dollars in millions, except per share data)
Three Months Ended
March 31,
18
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(1) Operating cash flow in 2017 has been reduced by $7.9 million as the result of implementation of ASU 2016-18. This amount represents the amount of
historical payments made on the Company’s zero-coupon subordinated notes deemed to be accreted interest.
Free Cash Flow: 2018 2017
Net cash provided by operating activities (1) 154.7$ 225.9$
Less: Capital expenditures (72.5) (72.2)
Free cash flow 82.2$ 153.7$
LABORATORY CORPORATION OF AMERICA HOLDINGS
Reconciliation of Non-GAAP Financial Measures
(Dollars in millions)
Three Months Ended
March 31,
19
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES - FOOTNOTES
1) During the first quarter of 2018, the Company recorded net restructuring and other special charges of $14.3 million. The charges included $11.3 million in
severance and other personnel costs along with $1.2 million in costs associated with facility closures and general integration initiatives and $2.3 million in
impairment to land held for sale. The Company reversed previously established reserves of $0.5 million in unused facility reserves.
The Company incurred integration and other related costs of $17.9 million primarily relating to the Chiltern acquisition. In addition, the Company incurred
$3.1 million in consulting expenses relating to fees incurred as part of its integration and management transition costs. During the quarter, the Company
paid a special one-time bonus of $31.0 million to its non-bonus eligible employees in recognition of the benefits the Company is receiving from the passage
of the Tax Cuts and Jobs Act of 2017 (TCJA). In addition, the Company incurred $1.7 million of non-capitalized costs associated with the implementation of
a major system as part of its LaunchPad business process improvement initiative. These items increased cost of sales by $24.8 million and selling, general
and administrative expenses by $28.9 million. The after tax impact of these charges decreased net earnings for the quarter ended March 31, 2018, by
$51.4 million and diluted earnings per share by $0.50 ($51.4 million divided by 103.4 million shares).
2) In its continuing assessment of the impact of the passage of the TCJA in the fourth quarter of 2017, the Company recorded a net increase in its provision
for income taxes (and a decrease of its net earnings) of $14.9 million, primarily relating to the repatriation tax, resulting in a decrease in its EPS of $0.15 for
the quarter ($14.9 million divided by 103.4 million shares). Given the significant changes resulting from the TCJA, the estimated financial impact in the
quarter is provisional and subject to further clarification, which could result in changes to these estimates during the remainder of 2018.
3) During the first quarter of 2017, the Company recorded net restructuring and other special charges of $3.9 million. The charges included $2.7 million in
severance and other personnel costs along with $1.6 million in costs associated with facility closures and general integration initiatives. The Company
reversed previously established reserves of $0.4 million in unused severance reserves.
The Company incurred legal and other costs of $0.9 million relating to the recently completed acquisitions. The Company also recorded $2.6 million in
consulting expenses relating to fees incurred as part of its Covance integration costs and compensation analysis, along with $0.9 million in short term equity
retention arrangements relating to the acquisition of Covance. In addition, the Company incurred $2.7 million of non-capitalized costs associated with the
implementation of a major system as part of its LaunchPad business process improvement initiative (all recorded in selling, general and administrative
expenses).
The after tax impact of these charges decreased net earnings for the quarter ended March 31, 2017, by $6.9 million and diluted earnings per share by
$0.07 ($6.9 million divided by 104.3 million shares).
20
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES - FOOTNOTES
4) The Company continues to grow the business through acquisitions and uses adjusted EPS excluding amortization as a measure of operational
performance, growth and shareholder returns. The Company believes adjusting EPS for amortization provides investors with better insight into the
operating performance of the business. For the quarters ended March 31, 2018 and 2017, intangible amortization was $62.3 million and $47.6 million,
respectively ($47.7 million and $32.4 million net of tax, respectively) and decreased EPS by $0.46 ($47.7 million divided by 103.4 million shares) and
$0.31 ($32.4 million divided by 104.3 million shares), respectively.